- Details
- Description
LuciAda 200 mg (Adagrasib) is a pharmaceutical product containing adagrasib, a targeted anticancer medicine that selectively inhibits the KRAS G12C protein. Adagrasib is designed to block abnormal KRAS G12C signaling, which can contribute to the growth and survival of cancer cells.
Adagrasib is used for the treatment of certain locally advanced or metastatic cancers with a confirmed KRAS G12C mutation, including specific cases of non-small cell lung cancer and other approved indications depending on the applicable regulatory market.
LuciAda 200 mg is an oral medicine intended for use under the supervision of a qualified healthcare professional. The appropriate dosage, treatment duration, monitoring, and management of potential adverse reactions should be determined by the treating physician based on the patient's condition and applicable prescribing information.
Product strength, packaging, manufacturer, availability, and regulatory status may vary by market and product presentation. Healthcare professionals and patients should consult the official product information before use.
